Tamsulosin

How to order Tamsulosin

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Tamsulosin on Prescriptsy

Tamsulosin is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Tamsulosin is an alpha-1A adrenergic receptor blocker used to treat the urinary symptoms of benign prostatic hyperplasia (BPH), commonly known as enlarged prostate.

It is one of the most widely prescribed medicines for lower urinary tract symptoms (LUTS) in men in the United Kingdom.

Tamsulosin works by selectively relaxing the smooth muscle in the prostate gland and bladder neck, improving urine flow and reducing bothersome symptoms such as difficulty starting urination, weak stream, frequent urination, urgency, and nocturia (getting up at night to urinate).

It is available as a prescription-only medicine (POM) and also as a pharmacy medicine (P) under the brand name Flomax Relief for men aged 45 to 75 who have been previously diagnosed with BPH.

Benign prostatic hyperplasia is one of the most common conditions affecting older men.

The prostate gland undergoes two main growth phases: during puberty and again from around age 25 onwards.

By age 50, approximately 50% of men have histological evidence of BPH, and by age 80, this rises to approximately 80%.

Not all men with BPH develop bothersome symptoms, but LUTS associated with BPH significantly affect quality of life, causing sleep disruption, social embarrassment, anxiety about bladder control, and reduced daily functioning.

This page provides a comprehensive clinical guide to tamsulosin, covering how it works, dosage instructions, side effects, safety warnings, and how to obtain the medicine in the United Kingdom.

Important safety information about tamsulosin

Before reading further, please note these essential safety points.

• Always inform your ophthalmologist if you take or have ever taken tamsulosin before cataract surgery, as it is associated with intraoperative floppy iris syndrome (IFIS).
• Take tamsulosin approximately 30 minutes after the same meal each day. Swallow the modified-release capsule whole; do not crush or chew.
• Tamsulosin may cause dizziness, especially when standing up quickly. Take care when getting up from sitting or lying.
• Tamsulosin provides symptomatic relief but does not shrink the prostate or prevent disease progression.
• If you develop complete inability to pass urine (acute urinary retention), seek urgent medical attention.

Understanding benign prostatic hyperplasia and LUTS

The prostate gland is a walnut-sized organ that sits below the bladder and surrounds the urethra (the tube that carries urine from the bladder to the outside of the body).

As men age, the prostate gradually enlarges due to proliferation of both stromal and glandular cells in the transitional zone, a process driven by dihydrotestosterone (DHT), the active metabolite of testosterone formed by the enzyme 5-alpha reductase.

This benign enlargement can compress the prostatic urethra and increase resistance to urinary outflow, causing the bladder to work harder to empty.

Lower urinary tract symptoms are divided into three categories. Storage symptoms (also called irritative symptoms) include urinary frequency, urgency, nocturia, and urge incontinence.

Voiding symptoms (also called obstructive symptoms) include hesitancy, poor or intermittent stream, straining to void, terminal dribble, and a sensation of incomplete bladder emptying.

Post-micturition symptoms include post-void dribble.

The severity of symptoms does not always correlate with prostate size, as both the static component (physical bulk of the prostate) and the dynamic component (smooth muscle tone in the prostate and bladder neck) contribute to obstruction.

Tamsulosin addresses the dynamic component.

NICE guideline CG97 (lower urinary tract symptoms in men) provides a structured approach to assessment and management.

Initial evaluation should include symptom assessment using the International Prostate Symptom Score (IPSS), a flow rate test, post-void residual volume measurement, urinalysis, and PSA testing if appropriate.

Conservative measures (reducing caffeine and alcohol intake, bladder training, fluid management) are first-line for mild symptoms. Pharmacological treatment is recommended when symptoms are moderate to severe and bothersome.

How tamsulosin works

Tamsulosin hydrochloride is a selective antagonist of alpha-1A adrenoceptors. Three subtypes of alpha-1 adrenoceptors exist: alpha-1A, alpha-1B, and alpha-1D.

Alpha-1A receptors predominate in the smooth muscle of the prostate gland, prostatic capsule, prostatic urethra, and bladder neck. Alpha-1B receptors predominate in vascular smooth muscle throughout the body.

Alpha-1D receptors are found in the detrusor muscle of the bladder and the spinal cord.

By selectively blocking alpha-1A receptors, tamsulosin causes relaxation of smooth muscle in the prostate and bladder neck, reducing the dynamic component of urethral obstruction.

This improves maximum urinary flow rate (Qmax), reduces post-void residual volume, and relieves both voiding and storage symptoms.

The selectivity of tamsulosin for alpha-1A over alpha-1B receptors means it has less effect on systemic blood pressure compared with non-selective alpha-blockers such as doxazosin, alfuzosin, and terazosin.

However, some degree of vascular effect remains, which is why dizziness and postural hypotension can still occur.

Tamsulosin is available as a modified-release (MR) formulation that provides sustained drug release over 24 hours.

This produces a stable plasma concentration profile with once-daily dosing and reduces peak-to-trough fluctuations, which helps minimise side effects related to transient high drug levels.

Clinical evidence for tamsulosin

Tamsulosin is one of the most extensively studied medicines for BPH-LUTS.

Pivotal randomised controlled trials demonstrated that tamsulosin 0.4 mg daily significantly improved IPSS scores (by approximately 4 to 6 points from baseline), maximum urinary flow rate (Qmax, by approximately 1.5 to 2.0 mL/s), and quality of life compared with placebo.

The onset of symptomatic improvement is typically within 1 to 2 weeks, with maximum benefit at 4 to 6 weeks.

The CombAT (Combination of Avodart and Tamsulosin) trial compared tamsulosin alone, dutasteride alone, and the combination in men with BPH and prostates larger than 30 mL.

After 4 years, the combination was superior to either monotherapy in reducing IPSS scores, improving flow rates, and reducing the risk of acute urinary retention and BPH-related surgery.

This established combination therapy as the standard of care for men with larger prostates and moderate-to-severe symptoms.

The Medical Therapy of Prostatic Symptoms (MTOPS) trial similarly demonstrated that combination therapy (doxazosin plus finasteride) was superior to either alone in preventing clinical progression of BPH.

While MTOPS used doxazosin rather than tamsulosin, the results support the principle of combining alpha-blocker and 5-alpha reductase inhibitor therapy.

Tamsulosin compared with other alpha-blockers

Several alpha-blockers are available for BPH-LUTS in the UK. Tamsulosin (selective alpha-1A blocker) is the most commonly prescribed because of its uroselective profile.

Alfuzosin (modified-release formulation) is an alternative with similar efficacy and tolerability.

Doxazosin is a non-selective alpha-blocker that also reduces blood pressure and may be useful in men who have both BPH and hypertension, but it carries a higher risk of postural hypotension and first-dose effect.

Terazosin is another non-selective alpha-blocker with a similar profile to doxazosin.

Silodosin is a newer highly selective alpha-1A blocker with slightly higher rates of ejaculatory dysfunction than tamsulosin but possibly less dizziness.

NICE guideline CG97 recommends offering an alpha-blocker as first-line pharmacological treatment for men with moderate-to-severe LUTS.

The guideline does not specify which alpha-blocker should be used first, but tamsulosin is the most commonly chosen agent in UK practice due to its favourable balance of efficacy, uroselective profile, and extensive clinical experience.

Dosage and administration

Take tamsulosin 400 micrograms (0.4 mg) modified-release capsule once daily, approximately 30 minutes after the same meal each day. Swallow the capsule whole with water.

Do not crush, chew, or open the capsule. Taking tamsulosin after food ensures consistent absorption. No dose titration is required.

Tamsulosin is a long-term treatment and should be continued for as long as symptoms warrant. If you stop taking tamsulosin, symptoms may return.

Side effects of tamsulosin

Common side effects

Dizziness (3% to 5%) is the most commonly reported side effect and is related to the alpha-blocking effect on blood pressure.

It is usually mild and most noticeable when standing up quickly.

Abnormal ejaculation (4% to 11%) is the other characteristic side effect, most commonly manifesting as retrograde ejaculation or reduced ejaculate volume.

Headache, nasal congestion, and fatigue occur in 1% to 3% of users.

Intraoperative floppy iris syndrome

IFIS is a recognised complication of cataract surgery in patients taking or who have previously taken tamsulosin.

The iris loses its rigidity during surgery, billowing and prolapsing towards the phacoemulsification probe. This increases the risk of posterior capsule rupture, iris trauma, and other intraoperative complications.

The MHRA has issued a Drug Safety Update advising that patients should always inform their ophthalmologist about current or past tamsulosin use.

The association between tamsulosin and IFIS was first described in 2005 and has since been confirmed in multiple observational studies.

When to seek medical advice

Seek urgent medical attention if you experience complete inability to pass urine (acute urinary retention).

Contact your GP if dizziness is severe or persistent, if you develop unexplained fever or signs of urinary infection, or if your symptoms worsen despite treatment.

Seek emergency help if you experience a prolonged erection lasting more than 4 hours, or a severe allergic reaction (difficulty breathing, swelling of face or throat).

Call 999 in an emergency. Report suspected adverse reactions to the MHRA at yellowcard.mhra.gov.uk .

Warnings and precautions

Prostate cancer screening

Before starting tamsulosin, prostate cancer should be excluded, as BPH and prostate cancer can coexist and produce similar symptoms.

Your GP should perform a digital rectal examination and may arrange a PSA blood test.

If the PSA is elevated or the prostate feels abnormal, referral for urological assessment (which may include prostate MRI and biopsy) is warranted.

Tamsulosin treats symptoms only and does not treat or prevent prostate cancer.

Cataract surgery

Always inform your ophthalmologist before any eye surgery that you take or have taken tamsulosin.

IFIS can complicate cataract surgery but can be managed if the surgeon is forewarned.

Some surgeons may advise stopping tamsulosin before surgery, but evidence on whether this reduces the risk is inconsistent. Never stop tamsulosin without medical advice.

Drug interactions

PDE5 inhibitors (sildenafil, tadalafil, vardenafil, avanafil) may cause additive hypotensive effects. Use with caution and start the PDE5 inhibitor at the lowest dose.

Do not combine tamsulosin with another alpha-blocker. Strong CYP3A4 and CYP2D6 inhibitors may increase tamsulosin levels. Antihypertensive medicines may have additive blood pressure-lowering effects.

Special populations

Tamsulosin is indicated for adult males only. It is not indicated in women or children.

No dose adjustment is needed for elderly patients, though they may be more susceptible to postural hypotension.

Mild to moderate renal or hepatic impairment does not require dose adjustment. Tamsulosin is contraindicated in severe hepatic impairment and not recommended in severe renal impairment.

How to get tamsulosin in the UK

Tamsulosin is available on NHS prescription from your GP or an authorised online prescriber registered with the General Pharmaceutical Council (GPhC).

The standard NHS prescription charge in England is 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

A pharmacy-only version, Flomax Relief MR 400 micrograms, is available without prescription from pharmacies for men aged 45 to 75 who have been previously diagnosed with BPH by a doctor.

The pharmacist will conduct a consultation and ask screening questions before supplying it.

Sources

• Tamsulosin hydrochloride, Summary of Product Characteristics (EMC)
• Tamsulosin hydrochloride, British National Formulary (BNF)
• LUTS in men, NICE CKS
• Prostate enlargement, NHS
• NICE CG97: Lower urinary tract symptoms in men
• MHRA Yellow Card Scheme